 Minor bleeding will be defined as any bleeding reported by the patient, which did not meet the criteria for major or clinically significant non-major bleeding. Economical comparisons will involve comparing all costs for treatment in both groups i.e. drugs, device, and all hospitalizations for the whole study period. Because the LAA is an important source of natriuretic peptides, and in some patients, the production of these hormones can be eliminated after LAA occlusion, natriuretic peptides and other inflammatory and thrombotic cytokines will be measured before, and 6 months after randomization and the concentrations will be compared. 